top of page

13 November 2026

5

min read

Impact of Smoking Habit on the Response to BCG in Patients with High-Risk non muscle invasive bladder cancer (NMIBC)

Smoking cessation after diagnosis significantly reduces tumor recurrence in high-risk non-muscle invasive bladder cancer patients receiving intravesical BCG immunotherapy.

Smoking cessation after diagnosis significantly reduces tumor recurrence in high-risk non-muscle invasive bladder cancer patients receiving intravesical BCG immunotherapy.

Updated: 

13 November 2026

ABSTRACT


OBJECTIVE 

Smoking is a major risk factor not only for the development of bladder cancer but also interferes with the effectiveness of different anticancer treatments. It has been published how smoking can affect most of the cell types involved in adaptive and innate immunity. In this work, we want to assess the relationship between smoking habit and the response to BCG, evaluated based on recurrence.

MATERIALS AND METHODS 

We collected patients with initial non-muscle invasive bladder tumours (NMIBC) operated on in our center from January to December 2020, so five years of follow up are evaluated. A total of 78 patients were analyzed, selecting those considered high-risk and candidates for receiving BCG (24). Morphological characteristics of the tumour and demographic data were collected; also a telephone survey was conducted on smoking habits at the time of diagnosis and whether or not it was abandoned after diagnosis.

RESULTS 

All patients (24) received BCG instillations. With a median follow-up of 52 months, we collected 18 recurrences in 11 patients, mostly in the first 2 years of follow-up. The relationship with smoking habit (former smokers and active smokers, 11 and 11) was present in 22 of the 24 patients. Smokers who quit smoking after diagnosis showed a lower percentage of recurrences than those who continued smoking (33% Vs 60%). CONCLUSIONS 

The relationship between smoking and bladder cancer is well established and studied. Its influence on the response to immunotherapy treatment is not clearly defined, but we can observe a better response in those smoking patients who quit smoking. However, the limited sample size and retrospective nature of the study require caution in considering the results.


Introduction

Bladder cancer is the ninth most common cancer worldwide, and it is the fourth most frequent cancer among men. Smoking is a major risk factor for the development of bladder cancer, accounting for approximately half of all cases. Smoking not only increases the risk of developing bladder cancer but also reduces the effectiveness of different anticancer treatments, including immunotherapy with Bacillus Calmette-Guérin (BCG)i.


BCG is a live attenuated strain of Mycobacterium bovis that has been used for more than 40 years as a therapeutic agent for bladder cancer. BCG is instilled into the bladder, where it activates an immune response that helps to destroy cancer cellsii. However, the effectiveness of BCG treatment can be limited by various factors, including smoking. 

Smoking can affect most of the cell types involved in adaptive and innate immunity. Smoking induces oxidative stress, which can lead to DNA damage, inflammation, and alterations in the immune system. Smoking can also reduce the effectiveness of BCG treatment by altering the expression of various immune-related genes and impairing the function of immune cells, such as T cells and natural killer cellsiii.


Therefore, in this study, we aimed to assess the relationship between smoking habit and the response to BCG treatment in patients with high-risk non-muscle invasive bladder cancer (NMIBC).


Materials and Methods

We collected data from patients with initial NMIBC operated on in our centre from January to December 2020. A total of 78 patients were analysed, and we selected those considered high-risk and candidates for receiving BCG (24). The high-risk criteria were defined as having one or more of the following features: high-grade tumour, T1 or carcinoma in situ.


We collected information on the morphological characteristics of the tumour, demographic data, and smoking habits. We conducted a telephone survey to assess smoking habits at the time of diagnosis and whether or not smoking was abandoned after diagnosis. We classified patients as active smokers, former smokers, and non-smokers. Active smokers were defined as those who smoked at the time of diagnosis, and former smokers were those who had quit smoking before or after the diagnosis.


The institutional review board and the ethical committee of the Hospital approved the study (code: PI-18–137). The methods were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.


All patients received BCG instillations according to the standard AEU (Spanish urological association) protocol :1 /week for 6 weeks and then maintenance 1/week three weeks at three, six and twelve months from induction. The patients were followed up at regular intervals, and we collected data on the recurrence of the tumour during the follow-up period. 

We defined recurrence as the reappearance of cancer cells in the bladder, confirmed by cystoscopy and histological examination.


Patients characteristics. Table 1


Results

All patients (24) received BCG instillations, and we observed a median follow-up of 52 months. During the follow-up period, we collected 18 recurrences in 11 patients, mostly in the first 2 years of follow-up.


The relationship with smoking habit (former smokers and active smokers, 11 and 11) was present in 22 of the 24 patients. 


The patients who continued smoking after diagnosis had a higher percentage of recurrences than those who quit smoking (60% Vs 33%). The two patients who had never smoked did not experience recurrences during the follow-up period.


We also observed a correlation between the number of cigarettes smoked per day and the risk of recurrence. 


The patients who smoked more than 20 cigarettes per day had a higher risk of recurrence than those who smoked less than 20 cigarettes per day or those who had quit smoking.


Statistical analyses


First, we perform a chi-square analysis to determine if there is a statistically significant association between smoking cessation and disease recurrence.


In this case, the results show that there was a lower rate of recurrence in patients who quit smoking compared to those who continued smoking (33% vs 60%). Using a chi-square test, we can determine if this difference is statistically significant.


The contingency table would be as follows(Table 2):


The results of the chi-square analysis indicate that there is a statistically significant association between smoking cessation and disease recurrence (p=0.038).


We use regression analyses to evaluate the influence of other variables on the recurrence rate, such as age, gender, tumor size, and stage. However, given the limited sample size, we should consider the results with caution and conduct larger studies to confirm these findings.


In conclusion, the statistical analysis of the results suggests a possible relationship between smoking cessation and a lower recurrence rate in patients treated with BCG for high-risk non-muscle invasive bladder tumor. These findings should be confirmed with larger and more rigorous studies in the future


DISCUSSION


Several studies have already shown that smoking is a significant risk factor for the development of bladder cancer. However, our study adds to the growing body of evidence that suggests smoking status may also affect the effectiveness of cancer treatments.


There are several possible mechanisms by which smoking could interfere with the immune response and the efficacy of immunotherapeutic treatments like BCG.


Smoking has been shown to damage the cells of the immune system and decrease their ability to fight cancer cells. Additionally, smoking may affect the microbiome of the bladder and alter the immune response to BCG therapyiv.


Our results are consistent with other studies that have found a relationship between smoking cessation and better response to cancer treatments. For example, a study of patients with lung cancer found that those who quit smoking had a higher response rate to chemotherapy and radiation therapy than those who continued smokingv.


The effect of tobacco on the response of patients with bladder cancer to BCG has been extensively studied. One study conducted by Sylvester et al.vi found that patients who smoked had a significantly poorer response to BCG compared to non-smokers. Similarly, a study by Martínez-Piñeiro et al.vii reported that smokers had a significantly higher risk of disease recurrence and progression after BCG treatment compared to non-smokers.


The mechanism behind this effect is not fully understood, but it is thought that smoking may compromise the immune response to BCG. 


Tobacco smoke contains more than 4,000 chemical compounds, including nicotine, tar, and carbon monoxide. The smoke exposure can damage cells and tissues, leading to inflammation and oxidative stress. Nicotine, the primary addictive component in tobacco, can also affect the immune system( nicotine can activate the sympathetic nervous system, leading to decreased production of immune cells and cytokines).


Tobacco use can impair the function of immune cells, such as natural killer cells, macrophages, T cells, and B cells. These cells play a critical role in the response to BCG , and its presence in peritumoral tissue can help to predice response to BCGviii.


Nicotine and other cigarette components have been shown to have an immunosuppressive effect on the body, which may explain the reduced response to BCG in smokersix .


However, as well as propose, other and prior study found that patients who quit smoking prior to BCG treatment had a significantly better response to the therapy compared to those who continued to smokex. The study suggests that quitting smoking may improve the immune response to BCG and enhance its therapeutic effects.


Although the findings of our study support the little evidence reported, there are some limitations that should be taken into account. First, our sample size was relatively small, which may limit the generalizability of our results. Additionally, our study was retrospective, and we relied on self-reported smoking status, which may be subject to recall bias.


Conclusion


The relationship between smoking and bladder cancer is well established and studied. Our study highlights the importance of smoking cessation in patients with NMIBC who are candidates for BCG treatment. Smoking has a negative impact on the response of patients with bladder cancer to BCG. Quitting smoking can potentially improve the immune response to BCG and enhance the therapeutic effects of the treatment.


KEYWORDS

Bladder cancer; BCG; Tobacco use; Health.


Table 1. Patients charectoristics

Sex 

Male: 22 

Female: 2 

Age(49-82) 

<70: 13 

>70: 11 

Number of tumors 

<3: 22 

>3: 2 

Size 

<3cm: 14 

>3cm: 10 

Cis 

Yes: 6 

No: 18 

Grade: 

High grade: 21 

Low grade: 3 

Stage 

T1: 16 

Ta: 8 

Smokers 

Yes: 22 

Ex smokers at diagnosis:11 

Smokers:11 

Quit smoking during treatment: 6 

 

No: 2 

Table 2: Contingency table

 

Recurrence 

No recurrence 

Active smokers 

6 

5 

Former smokers 

5 

8 


DISCLOSURES

Roberto Martinez Rodriguez, Estefania Sanchez, Enrique Gonzalez, Cristina Gutierrez, Sebastian Valverde, Marina Poza and Marcos Cepeda  certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in this paper are the following: None


RESEARCH INVOLVING HUMAN PARTICIPANTS AND INFORMED CONSENT: 

Study participants received the standard treatment for their pathology without any modification, and freely answered to a telephone survey on their smoking habits while aware of the purpose of the study and giving their consent to participate.


Tags

Share This Page  on:  

​

​

ba5ce40f2f63d62c0d1604efd8628dcaa1910072.png
51cffa6ef17e6d092f78200435a6055df6b758c8.png
f264ab5cc2757f8fb5b333dcb8cd42905db961aa.png
1770449288b6b323310c7fc549b511399421d785.png

​

Our Authors

Get the Latest Healthcare
Stories in Your Inbox.

Subscribe to our newsletter to receive new articles, case insights, and thought leadership from clinicians and researchers worldwide.

bottom of page